Sandoz has obtained the Food and Drug Administration’s blessing for a citrate-free high-concentration formulation of its biosimilar Hyrimoz (adalimumab-adaz) injection. The adalimumab citrate-free HCF ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, ...

On March 21, 2023, Sandoz, announced FDA approval of its citrate-free high-concentration formulation (HCF) of its biosimilar HYRIMOZ® (adalimumab-adaz) injection. HYRIMOZ® is approved to treat seven ...

Basel, July 21, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) has accepted for review its Supplemental Biologics ...

Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab). Sandoz ...

(RTTNews) - Sandoz (SDZNY) has unveiled Hyrimoz or adalimumab citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively ...

(RTTNews) - Sandoz said that the citrate-free high-concentration formulation or HCF of its biosimilar Hyrimoz (adalimumab-adaz) injection will be available in the United States starting July 1.

The FINANCIAL — Sandoz, a Novartis division and one of the global leaders in biosimilars, announced a global resolution of all intellectual property related litigation with AbbVie concerning the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the third biosimilar to adalimumab, adalimumab-adaz, for all eligible indications of the ...

Novartis’ Sandoz is pushing to wipe out an advantage AbbVie’s Humira enjoys over its biosimilar rival in the EU, securing regulatory acceptance of a filing for a high-concentration formulation of the ...